Assessing the construct validity and responsiveness of Preference-Based Measures (PBMs) in cataract surgery patients.


Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
Jul 2020
Historique:
accepted: 08 02 2020
pubmed: 23 2 2020
medline: 28 7 2020
entrez: 22 2 2020
Statut: ppublish

Résumé

The validity and responsiveness of the EQ-5D-3L in visual conditions has been questioned, inspiring development of a vision 'bolt-on' domain (EQ-5D-3L + VIS). Developments in preference-based measures (PBM) also includes the EQ-5D-5L and the ICECAP-O capability wellbeing measure. This study aimed to examine the construct validity and responsiveness of the EQ-5D-3L, EQ-5D-5L, EQ-5D-3L + VIS and ICECAP-O in cataract surgery patients for the first time, to inform choice of PBM for economic evaluation in this population. The analyses used data from the UK Predict-CAT cataract surgery cohort study. PBMs and the Cat-PROM5 [a validated measure of cataract quality of life (QOL)] were completed before surgery and 4-8 weeks after. Construct validity was assessed using correlations and known-group differences evaluated using regression. Responsiveness was evaluated using effect sizes and analysis of variance to compare change scores between groups, defined by patient-reported and clinical outcomes. The sample comprised 1315 patients at baseline. No PBMs were associated with visual acuity and only the ICECAP-O (Spearman's rs =  - 0.35), EQ-5D-3L + VIS (rs =  - 0.42) and EQ-5D-5L (Value Set for England rs =  - 0.31) correlated at least moderately with the Cat-PROM5. Effect sizes of change were consistently largest for the EQ-5D-3L + VIS (range 0.34-0.41), followed by the ICECAP-O (range 0.20-0.34). Results indicated no improvement in responsiveness using the EQ-5D-5L (range 0.13-0.16) compared to the EQ-5D-3L (range 0.17-0.20). Whilst no PBMs comprehensively demonstrated evidence of construct validity and responsiveness in cataract surgery patients, the ICECAP-O was the most responsive generic PBM to improvements in QOL. Surprisingly the EQ-5D-5L was not more responsive than the EQ-5D-3L in this setting.

Identifiants

pubmed: 32080789
doi: 10.1007/s11136-020-02443-3
pii: 10.1007/s11136-020-02443-3
pmc: PMC7295830
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1935-1946

Subventions

Organisme : Department of Health
ID : RP-PG-0611-20013
Pays : United Kingdom
Organisme : Programme Grants for Applied Research
ID : RP-PG-0611-20013

Références

Qual Life Res. 2012 Feb;21(1):167-76
pubmed: 21598064
J Cataract Refract Surg. 2016 Dec;42(12):1759-1767
pubmed: 28007107
Value Health. 2012 May;15(3):550-61
pubmed: 22583466
Health Econ. 2008 Jun;17(6):667-70
pubmed: 18457341
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
Pharmacoeconomics. 2018 Jun;36(6):699-713
pubmed: 29476363
Optom Vis Sci. 2013 Aug;90(8):861-6
pubmed: 23851304
Pharmacoeconomics. 2018 Jun;36(6):645-661
pubmed: 29572719
Qual Life Res. 2019 Jun;28(6):1429-1439
pubmed: 30666550
Pharmacoeconomics. 2017 Dec;35(Suppl 1):21-31
pubmed: 29052157
Patient. 2019 Aug;12(4):383-392
pubmed: 30607809
Invest Ophthalmol Vis Sci. 2008 Jan;49(1):1-6
pubmed: 18172067
Health Technol Assess. 2014 Feb;18(9):1-224
pubmed: 24524660
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
J Cataract Refract Surg. 2014 Jul;40(7):1163-9
pubmed: 24957436
Value Health. 2015 Jan;18(1):52-60
pubmed: 25595234
JAMA. 2019 Jun 4;321(21):2067-2068
pubmed: 30946431
J Clin Epidemiol. 2011 May;64(5):497-506
pubmed: 20685077
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3278-81
pubmed: 12882770
J Cataract Refract Surg. 2009 Mar;35(3):504-13
pubmed: 19251145
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):5872-5881
pubmed: 27802517
Eye (Lond). 2018 Apr;32(4):796-805
pubmed: 29521952
Pharmacoeconomics. 2015 Nov;33(11):1137-54
pubmed: 26040242
J Cataract Refract Surg. 2002 Oct;28(10):1742-9
pubmed: 12388022
Value Health. 2019 Jan;22(1):50-61
pubmed: 30661634
Acta Med Port. 2014 Mar-Apr;27(2):236-45
pubmed: 24813493
Soc Sci Med. 2006 Apr;62(8):1891-901
pubmed: 16168542
Eye (Lond). 2018 Apr;32(4):788-795
pubmed: 29386619
Med Care. 2004 Sep;42(9):851-9
pubmed: 15319610
Soc Sci Med. 2008 Sep;67(5):874-82
pubmed: 18572295
Ophthalmic Epidemiol. 2010 Jun;17(3):152-9
pubmed: 20455844
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137
pubmed: 28194657
Value Health. 2010 Jun-Jul;13(4):487-94
pubmed: 20230549
Health Qual Life Outcomes. 2003 Oct 16;1:54
pubmed: 14613568
BMC Health Serv Res. 2008 Apr 08;8:76
pubmed: 18397519
Br J Ophthalmol. 2007 Jul;91(7):927-32
pubmed: 17272387
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234
pubmed: 29032195

Auteurs

Katie Breheny (K)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. katie.breheny@bristol.ac.uk.

William Hollingworth (W)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Rebecca Kandiyali (R)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Padraig Dixon (P)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Abi Loose (A)

Department of Ophthalmology, Bristol Eye Hospital, Bristol, UK.

Pippa Craggs (P)

Department of Ophthalmology, Bristol Eye Hospital, Bristol, UK.

Mariusz Grzeda (M)

Department of Ophthalmology, Bristol Eye Hospital, Bristol, UK.

John Sparrow (J)

Department of Ophthalmology, Bristol Eye Hospital, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH